CY1121020T1 - Φαρμακοτεχνικη μορφη παρβοϊου για τη θεραπευτικη αντιμετωπιση ογκων - Google Patents
Φαρμακοτεχνικη μορφη παρβοϊου για τη θεραπευτικη αντιμετωπιση ογκωνInfo
- Publication number
- CY1121020T1 CY1121020T1 CY181101367T CY181101367T CY1121020T1 CY 1121020 T1 CY1121020 T1 CY 1121020T1 CY 181101367 T CY181101367 T CY 181101367T CY 181101367 T CY181101367 T CY 181101367T CY 1121020 T1 CY1121020 T1 CY 1121020T1
- Authority
- CY
- Cyprus
- Prior art keywords
- parvovirus
- treatment
- mmol
- virus
- rat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Περιγράφεται φαρμακοτεχνική μορφή παρβοϊού, η οποία περιλαμβάνει (α) τουλάχιστον 1 x 109 pfu/ml παρβοϊού H1 (H-1PV), ή έναν συγγενή παρβοϊό τρωκτικών που επιλέγεται από την ομάδα που αποτελείται από LuIII, μικρό ιό ποντικού (MMV), παρβοϊό ποντικού (MPV), μικρό ιό αρουραίου (RMV), παρβοϊό του αρουραίου, ή ιό αρουραίου (RV) και (β) ένα φαρμακευτικώς αποδεκτό φορέα που περιέχει 40-50% ιοδιξανόλη (β/ο), 0,7-0,9 mmol CaC12 x 2 Η2O, 50-60 mmol NaCl, 0,9-1,2 mmol KC1, 0,7-0,95 mg/ml Τρομεθαμίνη και 0,05-0,15 mg/ml άλας EDTA με ασβεστιονάτριο. Μία προτιμώμενη χρήση είναι η θεραπεία όγκου του εγκεφάλου με ενδομυϊκή ένεση.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15173308.6A EP3108892A1 (en) | 2015-06-23 | 2015-06-23 | Parvovirus formulation for treating tumors |
| PCT/EP2016/059832 WO2016206844A1 (en) | 2015-06-23 | 2016-05-03 | Parvovirus formulation for treating tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121020T1 true CY1121020T1 (el) | 2019-12-11 |
Family
ID=53488216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181101367T CY1121020T1 (el) | 2015-06-23 | 2018-12-19 | Φαρμακοτεχνικη μορφη παρβοϊου για τη θεραπευτικη αντιμετωπιση ογκων |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10624935B2 (el) |
| EP (2) | EP3108892A1 (el) |
| JP (1) | JP6423113B2 (el) |
| KR (1) | KR102046239B1 (el) |
| CN (1) | CN107921075B (el) |
| AU (1) | AU2016284497B2 (el) |
| BR (1) | BR112017025157B1 (el) |
| CA (1) | CA2990749C (el) |
| CL (1) | CL2017003338A1 (el) |
| CY (1) | CY1121020T1 (el) |
| DK (1) | DK3277299T3 (el) |
| ES (1) | ES2702526T3 (el) |
| HK (1) | HK1254253B (el) |
| HR (1) | HRP20182163T8 (el) |
| HU (1) | HUE041557T2 (el) |
| IL (1) | IL255952B (el) |
| LT (1) | LT3277299T (el) |
| MX (1) | MX2017014897A (el) |
| NZ (1) | NZ737222A (el) |
| PL (1) | PL3277299T3 (el) |
| PT (1) | PT3277299T (el) |
| RS (1) | RS58096B1 (el) |
| RU (1) | RU2698717C2 (el) |
| SA (1) | SA517390457B1 (el) |
| SI (1) | SI3277299T1 (el) |
| TR (1) | TR201819816T4 (el) |
| WO (1) | WO2016206844A1 (el) |
| ZA (1) | ZA201707502B (el) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3225253A1 (en) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| ES2402138T3 (es) | 2007-12-28 | 2013-04-29 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Terapia contra el cáncer con un parvovirus combinado con quimioterapia |
| DK2332986T3 (da) * | 2009-12-11 | 2013-12-16 | Deutsches Krebsforsch | Antistof som binder til H-1 parvovirus |
| EP2366398A1 (en) | 2010-03-17 | 2011-09-21 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with an HDAC inhibitor |
| EP2397542A1 (en) * | 2010-06-17 | 2011-12-21 | Deutsches Krebsforschungszentrum | Modified parvovirus having enhanced anti-tumour efficacy |
-
2015
- 2015-06-23 EP EP15173308.6A patent/EP3108892A1/en not_active Withdrawn
-
2016
- 2016-05-03 PT PT16725045T patent/PT3277299T/pt unknown
- 2016-05-03 NZ NZ73722216A patent/NZ737222A/en unknown
- 2016-05-03 MX MX2017014897A patent/MX2017014897A/es active IP Right Grant
- 2016-05-03 WO PCT/EP2016/059832 patent/WO2016206844A1/en active Application Filing
- 2016-05-03 HU HUE16725045A patent/HUE041557T2/hu unknown
- 2016-05-03 DK DK16725045.5T patent/DK3277299T3/en active
- 2016-05-03 RU RU2017139565A patent/RU2698717C2/ru active
- 2016-05-03 BR BR112017025157-4A patent/BR112017025157B1/pt active IP Right Grant
- 2016-05-03 CN CN201680036327.1A patent/CN107921075B/zh active Active
- 2016-05-03 LT LTEP16725045.5T patent/LT3277299T/lt unknown
- 2016-05-03 PL PL16725045T patent/PL3277299T3/pl unknown
- 2016-05-03 ES ES16725045T patent/ES2702526T3/es active Active
- 2016-05-03 CA CA2990749A patent/CA2990749C/en active Active
- 2016-05-03 KR KR1020177036934A patent/KR102046239B1/ko active IP Right Grant
- 2016-05-03 AU AU2016284497A patent/AU2016284497B2/en active Active
- 2016-05-03 TR TR2018/19816T patent/TR201819816T4/tr unknown
- 2016-05-03 JP JP2017566665A patent/JP6423113B2/ja active Active
- 2016-05-03 RS RS20181557A patent/RS58096B1/sr unknown
- 2016-05-03 EP EP16725045.5A patent/EP3277299B1/en active Active
- 2016-05-03 SI SI201630142T patent/SI3277299T1/sl unknown
-
2017
- 2017-11-06 ZA ZA2017/07502A patent/ZA201707502B/en unknown
- 2017-11-27 IL IL255952A patent/IL255952B/en active IP Right Grant
- 2017-11-30 SA SA517390457A patent/SA517390457B1/ar unknown
- 2017-12-04 US US15/830,489 patent/US10624935B2/en active Active
- 2017-12-22 CL CL2017003338A patent/CL2017003338A1/es unknown
-
2018
- 2018-10-18 HK HK18113397.2A patent/HK1254253B/zh unknown
- 2018-12-19 CY CY181101367T patent/CY1121020T1/el unknown
- 2018-12-20 HR HRP20182163TT patent/HRP20182163T8/hr unknown
-
2020
- 2020-03-20 US US16/824,791 patent/US11324788B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
| EA201790174A1 (ru) | Антипролиферативные соединения и способы их применения | |
| CY1125163T1 (el) | 2΄-υποκατεστημενα-ν6-υποκατεστημενα πουρινο νουκλεοτιδια για την θεραπεια ιων rna | |
| PH12016501693A1 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| EA201691448A1 (ru) | Гибридосомы, содержащие их композиции, способы их получения и их применения | |
| MD4584C1 (ro) | (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1ʹ,2ʹ:4,5]pirazino[2,1-b][1,3]oxazepin-8-olat de sodiu | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| EA202090720A1 (ru) | ПРОИЗВОДНЫЕ GalNAc | |
| CO2019011578A2 (es) | Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo | |
| JP2017514910A5 (el) | ||
| EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
| ECSP17069696A (es) | Compuestos novedosos | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| MX2021012096A (es) | Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo. | |
| EA201890221A1 (ru) | Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| CY1121020T1 (el) | Φαρμακοτεχνικη μορφη παρβοϊου για τη θεραπευτικη αντιμετωπιση ογκων | |
| EA201792094A1 (ru) | Ингибиторы полимеразы вируса гепатита c |